STOCKS TELEGRAPH

Tag: healthcare

  • Grove Inc. (GRVI) Stock Surges Following Announcement of Successful Fiscal 2021 Financial Reports

    Grove Inc. (GRVI) stock prices were up 35.54% as of the market opening on July 28th 2021, bringing the price per share up to USD$6.30 early on in the trading day.

    Revenue and Net Income Reports

    July 28th 2021 saw GRVI stock, the Nevada based company that is revolutionizing the hemp industry, report preliminary and unaudited financial results for the fourth quarter of fiscal 2021, ended June 30th 2021. The company reported revenues ranging from USD$10.1 million to USD$10.4 million, representing a massive 300% increases over the numbers reported for the prior year quarter. Net income is expected to range from USD$1.5 million to USD$2 million, up from a net loss of more than USD$700,000 in the fourth quarter of fiscal 2020.

    2021 Full Year Report

    GRVI stock reported expecting full year revenues for the full fiscal year in the amount of USD$23.6 million to USD$23.9 million, a substantial 200% increase over the USD$7.4 million reported for the fiscal year 2020. Net income for the 2021 year is expected to range from USD$2 million to USD$2.5 million, up from a considerable net loss of USD$5 million for the fiscal year 2020. Full financial results for the fiscal year 2021 are expected around September 15th 2021.

    GRVI Stock Exceeding Expectations

    The company is pleased to announce having exceeded all of its internal projections for growth and profitability over the course of 2021 so far. Driven by a combination of a stellar workforce and an effectively executed business strategy, the company continued to expand the scope of its growth while sustaining profitability.

    GRVI Stock Planning to Reinvest

    The company is keen to enter the fiscal year 2022 riding the momentum generated over the fiscal year 2021. The current years financial success afford the company flexibility in investing to further consolidate and enhance internal growth. A solid balance sheet and continued positive cash flow from operations will see the company invest heavily in facilitating the growth of GRVI stock’s Products and Manufacturing. Investments are also expected to be made in an Extraction and Lab Facility to pioneer the R&D in the Hemp and Wellness industries.

    Future Outlook for GRVI

    Armed with the immense success of its preliminary and unaudited financial reports for the fiscal year 2021, GRVI stock is poised to capitalize on its momentum. The company is keen to continue its trajectory of success into the new fiscal year, hoping to drive additional growth. Investors are hopeful that management will continue to execute its strategy so as to usher in further gains in shareholder value.

  • PolarityTE Inc. (PTE) Stock on the Rise Following Announcement of Positive Topline Data from SkinTE Clinical Trial

    PolarityTE Inc. (PTE) stock prices were up 4.84% as of the market opening on July 28th, 2021, bringing the price per share up to USD$0.85 early on in the trading day.

    SkinTE Clinical Trial

    July 28th, 2021 saw the company announce the final data from its multi-center, randomized, and controlled trial, designed to evaluate the treatment of Diabetic Foot Ulcers. PTE stock’s proprietary investigational product SkinTE, in combination with standard of care, was evaluated against just standard of care alone.

    PTE Stock’s Trial’s Success

    PTE stock reported having successfully met the primary endpoint of the trial of wound closure by the twelfth week of treatment. The secondary endpoint of Percent Area Reduction (PAR) was also met, having been assesses for every even-numbered week from the fourth to the twelfth. The trial had a total enrolment of 100 participants that were split into two equal groups, with one received SOC plus SkinTE, whereas the other cohort received only SOC. The trial was conducted and evaluated across 13 different sites.

    Trial Results

    35 out of the 50 patients, representing 70% of the cohort, who received SkinTE in conjunction with SOC exhibited wound closure at 12 weeks. This is comparable to the 17 patients out of 50, representing 34%, exhibiting wound closure by week 12 with SOC only. 45 out of the 50 patients who received the SkinTE plus SOC treatment received a single application of SkinTE. Treatment with SkinTE in tandem with SOC resulted in an increase in the odds of would closure by a massive 5.37 times versus SOC alone.

    Adverse Event Reports

    The trial reported 148 Adverse events that were attributable to 49 subjects. The SkinTE plus SOC treatment cohort reported 66 AEs among 21 subjects while the SOC treatment group reported 82 Adverse Events, attributable to 28 subjects. Of this total, 26 incidents were Serious Adverse Events, with 12 occurring in the SkinTE plus standard of care across 7 subjects. 14 Serious Adverse Events were reported for the standard of care cohort, allocated across a total of 9 subjects.

    Future Outlook for PTE Stock

    Armed with the resounding success of the results of its SkinTE clinical trial, PTE Stock is poised to capitalize on the opportunities for the proliferation of the treatment. The company is keen to allocate resources towards consolidating and expanding its market footprint. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • electroCore Inc. (ECOR) Stock on the Rise Following Announcement of Newly Issued Patent

    electroCore Inc. (ECOR) stock prices were up 3.92% as of the market closing on July 27th, 2021, bringing the price per share up to USD$0.9665 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 5.54%, bringing it up to USD$1.02.

    ECOR Stock’s Patent

    July 27th, 2021 announced that the United States Patent and Trademark Office (USPTO) has granted ECOR stock U.S. Patent No. 11,065,444. The patent issued to the commercial-stage bioelectronic medicine company is in regard to the use of a mobile phone for the stimulation of the trigeminal nerve to treat disorders. The new patent is owned by the company and is the most recent U.S patent to be issued in connection with the company’s development of non-invasive solution programs for pain.

    Patented Technology

    The newly issued patent includes descriptions of devices and methods that can be used by patients themselves to treat medical conditions, such as migraine headaches, with non-invasive means. ECOR stock achieves this by the electrical stimulation of nerves in the head, particularly supraorbital, supratrochlear, infraorbital, and mental nerves in the general area of patients’ foramen or notch.

    About the Treatment

    The system consists of a handheld mobile device, like a smartphone, that is applied to the surface of the head of the patient being treated. Electrical impulses are applied through the patient’s skin via one or more electrodes, serving to modulate a targeted nerve to treat the medical condition. ECOR stock’s system aims to provide patients with a self-treatment solution in the absence of a medical professional.

    Expansive Scope of Treatment

    ECOR stock is keen to continue the advancement of its non-invasive treatment solutions for its patients. The new development massively increases the scope of the reach and accessibility by which the company’s therapy may be deployed. This facilitates more patients all over the world to get the relief they need while not having to leave the comfort of their homes. This is line with the company’s vision of improving patient outcomes with its nerve stimulation therapy platform, which initially focused on the treatment of various neurological conditions.

    Future Outlook for ECOR Stock

    Armed with the security of the patenting of its proprietary technology, ECOR stock is poised to capitalize on the opportunities and tenure afforded to it over the long term. The company is keen to spearhead market penetration in an effort to usher in significant and sustained increases in shareholder growth.

  • Sintx Technologies, Inc. (SINT) Stock Undergoes Volatility Following News of First FleX SN-PEEK Shipment

    Sintx Technologies, Inc. (SINT) stock prices were up 11.04% as of the market closing on July 27th, 2021, bringing the price per share up to USD$1.71 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 5.85%, bringing it down to USD$1.61.

    FleX SN-PEEK Shipments

    July 27th, 2021 saw SINT stock announce the first shipment of FleX SN-PEEK, its new product that is designed to be used in orthopedic implants. The company’s proprietary product commenced being shipped on July 20th, 2021, combining the singular bioactivity of silicon nitride with the properties of Zeniva PEEK, which was supplied by Solvay.

    About FleX SN-PEEK

    The composite material has been deemed to have a myriad of applications, ranging from spine surgery to joint replacements to craniomaxillofacial medical devices. On the basis of data collected by SINT stock on silicon nitride, FleX SN-PEEK is expected to facilitate faster bone healing, improved radiographic imaging, avoid metal ion release in the body, and have broad-spectrum resistance to infection as compared to PEEK in isolation.

    Advantages of FleX SN-PEEK

    The commencement of the shipping of SINT stock’s FleX SN-PEEK is a major milestone for the company. It continues to allocate resources to leverage the osteogenic and antipathogenic properties of silicon nitride for biomedical applications. The company is confident that the product differentiates itself as being superior with many unmatched benefits. Zaniva PEEK is a biomaterial that has been determined to have many advantages, signaled by its worldwide use. The advantages include favorable material modules, ease of manufacturing, established clinical record, as well as a track record of use in orthopedics.

    SINT Stock Healthcare Scope

    The combination of PEEK with silicon nitride’s osteogenic and antipathogenic properties gives rise to a superior product, FleX SN-PEEK. The catalogue of FleX SN-PEEK products provides access to new biomedical areas like craniomaxillofacial, and foot osteotomy and fusion. The proprietary technology serves to address a large unmet need stemming from surgeons constantly on the lookout for materials and procedures that result in improved outcomes with mitigated complications.

    Future Outlook for SINT

    Armed with the success of the first delivery of its proprietary technology, SINT stock is poised to capitalize on the continued development of FleX SN-PEEK. The company is keen to expand and consolidate its market footprint in order to continue its trajectory of success. Investors are hopeful that management will be able to allocate resources so as to ensure maximum gains in shareholder value.

  • Relmada Therapeutics Inc. (RLMD) Stock Continues Downward Trend Despite Promising Top-line Data from REL-1017 Study

    Relmada Therapeutics Inc. (RLMD) stock prices were down 3.26% some time after market trading commenced on July 27th, 2021, bringing the price per share down to USD$24.30 early on in the trading day.

    Positive REL-1017 Topline Data

    July 27th 2021 announced the top-line results of the human abuse potential study with REL-1017, the company’s lead candidate. The novel NMDA receptor channel blocker is in Phase 3 development for the treatment of the major depressive disorder (MDD). Top-line results indicated all three doses of REL-1017 tested in recreational opioid users demonstrated a highly statistically significant difference from the control group. The 25mg, 75mg, and 150mg therapeutic, supratherapeutic, and maximum tolerated doses were compared to the active control drug, oxycodone 40 mg.

    RLMD Stock’s Study Endpoints

    The primary endpoint of the study was a measure of ‘likability’ with the subjects rating the maximum effect for Drug Liking “at the moment” using a 1=100 bipolar rating scale. The visual analog scale (VAS) has 100 as the highest likeability, 50 as the neutral, and the 0 as the highest dislike. The data clearly shows a very meaningful difference between the REL-1017 treatment and oxycodone at all three tested doses.

    Safety of REL-1017

    The results consolidate previous findings about the lack of opioid effects of REL-1017. RLMD stock is keen to continue the clinical development of REL-1017 as a novel, safe, and rapidly effective treatment for MDD. The findings have been consistent with RLMD stock’s development programs and confirms what has already been established by an extensive body of literature that indicates the lack of abuse potential of REL-1017. The results strongly support the ongoing REL-1017 late-stage development program.

    Consolidated Scope for RLMD Stock

    The results are in line with HAP results that have been seen for other drugs that affect the CNS and have been scheduled at Classes IV or V, or remain unscheduled, during the assessment and review period. RLMD stock is keen to address the large unmet need for patients suffering from depression in the absence of safe and rapidly effective treatments.

    Future Outlook for RLMD

    Armed with the promising topline results from its study of REL-1017, RLMD is poised to capitalize on the enormous marketspace it finds needing to be addressed. Current and potential investors are hopeful that management will be able to leverage the resources at their diposal to facilitate significant and sustained increases in shareholder value.

  • Travena, Inc. (TRVN) Stock Exhibits Minor Volatility Following First Patient Enrolment in ACTIV-4 Host Tissue Trial

    Travena, Inc. (TRVN) Stock Exhibits Minor Volatility Following First Patient Enrolment in ACTIV-4 Host Tissue Trial

    Travena, Inc. (TRVN) stock prices were down 3.24% shortly after market trading commenced on July 27th, 2021, bringing the price per share down to USD$1.3464.

    First Patient Enrolment

    July 26th, 2021 saw TRVN stock announce the enrollment of its first patient in the ACTIV-4 Host Tissue (Accelerating Covid-19 Therapeutic Interventions and Vaccines) trial. With the end of Covid-19 requiring a multi-pronged solution, TRVN stock is excited to be developing TRV027 as a pioneering active treatment arm available for patient randomization.

    ACTIV-4 Host Tissue Trial

    The ACTIV-4 Host Tissue trial serves to evaluate four investigational agents that fight dysregulation of the renin-angiotensin-aldosterone system (RAAS) and immune system irregularities caused by Covid-19 infections. The treatment is a novel AT1 receptor selective agonist that targets the AT1 receptor to bind to within the RAAS, thereby obstructing the damaging pathway that results in acute lung damage and abnormal blood clotting. TRVN stock’s treatment activates the cellular pathway that selectively targets reparative actions that improve lung function and promote anti-inflammatory effects.

    TRVN Stock’s Efforts Against Pandemic

    More than 1600 patients will be enrolled across 50 sites spanning the United States for the TRVN stock’s trial. TRV027 is part of the initial trial launch, with additional study arms being added to the trial over time. The study will serve to evaluate the impact of each intervention on recovery, supplemental oxygen use, need for mechanical ventilation, organ failure, and mortality. As the global Covid-19 pandemic continues to devastate the globe, the development of interventions remains a top priority, aiming to combat the vascular, fibrotic, and inflammatory damage done by the virus.

    About the Trial

    The ACTIV-4 Host Tissue is a multi-site, randomized, placebo-controlled clinical trial with multiple treatment arms. Each arm is expected to enroll roughly 300-400 Covid-19 patients that are 18 years of age or older. The four trial arms will test investigational agents that target the RAAS or immune system through distinct mechanisms of action. The trial is designed for TRVN stock to determine whether modulation of these systems is a viable solution to preventing progression to critical illness in hospitalized Covid-19 patients.

    Future Outlook for TRVN Stock

    Armed with the initiation of patient testing in its ACTIV-4 Host Tissue trial, TRVN stock is poised to capitalize on the opportunities afforded to it. The company is keen to leverage the resources at its disposal to usher in significant long-term growth, which investors hope will translate into gains in shareholder value.

  • Abeona Therapeutics, Inc. (ABEO) Stock Relatively Stable Following Positive Data for Sanfilippo Syndrome Treatment

    Abeona Therapeutics, Inc. (ABEO) stock prices were up 0.76% as of the market close on July 26th, 2021, bringing the price per share up to USD$1.32 at the end of the trading day. Subsequent current market fluctuations saw the stock fall by 5.30%, bringing it down to USD$1.25.

    Promising Topline Data

    July 26th, 2021 saw ABEO stock announce magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A clinical study. The study indicated that ABO-102 increases grey matter, corpus callosum, and amygdala volumes in the brain. The study consisted of three young patients with Sanfilippo Syndrome Type A (MPS IIIA) at 24 months, compared to afflicted patients who did not receive treatment. The findings were presented by ABEO stock during an oral presentation at the 16th International Symposium on MPS and Related Diseases.

    Scope of Findings

    Brain volume loss is typical in children with MPS IIIA and is linked to long-term cognitive and physical disability. Grey matter has been found to be important for cognitive development, whereas the corpus callosum is crucial for motor function. The amygdala plays a critical role in fear learning as well as social/emotional development. The findings highlight the potential of ABO-102 to increase brain grey matter, corpus callosum, and amygdala volumes. This potential is in line with ABEO stocks’ previously reported results of preservation of neurocognitive development in the three young patients in the Transpher A study.

    ABEO Stock’s Study Endpoints

    The Transpher A study primary endpoints targeted neurodevelopment and the treatment’s safety. Secondary endpoints include, but are not limited to, brain volume, behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, heparan sulfate levels in CSF, plasma, and urine, and liver volume.

    About the Study

    The Transpher A Study is a two-year process that is currently ongoing as an open-label, dose-escalation, Phase 1/2 global clinical trial. It is designed to assess the treatment of patients with Sanfilippo syndrome type A (MPS IIIA) with the use of ABEO stock’s ABO-102. The study is known as ABT-001 and is intended for patients ranging from birth to 2 years of age, or for patients older than 2 years with a cognitive developmental quotient of 60% or above.

    Future Outlook for ABEO

    Armed with the latest data from its highly promising study, ABEO stock is poised to capitalize on the opportunities ahead of it. The company is keen to push for the accelerated development and proliferation of ABO-102, which investors hope will translate into long-term gains in shareholder value.

  • ObsEva SA (OBSV) Stock Skyrockets Following Global License Agreement with Organon

    ObsEva SA (OBSV) stock prices were up by 2.02% as of the market closing on July 26th, 2021, bringing the price per share up to USD$2.52 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 32.94%, bringing it up to USD$3.35.

    OBSV Stock Partners with Organon

    July 27th 2021 saw OBSV stock announce having entered into an agreement with Organon, wherein Organon will license the global development, manufacturing, and commercial rights to ebopriprant (OBE022). The treatment is an investigational, orally active, selective prostaglandin F2α receptor antagonist that is being evaluated as a potential treatment for preterm labor. It is designed to reduce inflammation and uterine contractions. Pending approval, the treatment has the potential to be a first-in-class innovation for a problem that is widespread and serious. Currently, there are no approved therapies for the acute treatment of preterm labor in the United States.

    Ebopriprant (OBE022)

    The asset is currently in the development-stage and is being studied to address a leading unmet need for women around the world. The agreement is set to consolidate the company’s path to sustained growth over the long term as it helps build Organon’s women’s health research and development portfolio. The partners share a vision to improve the women’s health landscape around the world, hoping to revolutionize the healthcare space.

    Facilitating Development

    Organon is an ideal strategic partner for OBSV stock in the collaborative drive to develop and commercialize ebopriprant. Collaboration is a critical step in advancing the investigational agent. While preterm births are on the rise, no other known compounds are currently in development. For this reason, the company is focused on evaluating the treatment of a significant area of unmet need.

    Details of Agreement

    As per the terms of the agreement, Organon is set to acquire exclusive global rights to develop and commercialize the treatment. OBSV stock will receive compensation via tiered double-digit royalties on commercial sales, as well as up to USD$500 million paid upfront and through milestone payments. Upon signing, OBSV is set to receive USD$25 million, up to USD$90 million in development and regulatory milestones, and up to USD$385 million sales based milestones.

    Future Outlook for OBSV

    Armed with its expansive new strategic partnership, OBSV stock is poised to capitalize on the additional opportunities within its reach. The company is keen to leverage the resources at its disposal to drive organic growth over the long term, thereby facilitating increases in shareholder value.

  • TRxADE HEALTH, Inc. (MEDS) Stock Dips Significantly Following Disclosure of Q2 2021 Financial Reports

    TRxADE HEALTH, Inc. (MEDS) stock prices were down 4.01% as of the market closing on July 26th, 2021, bringing the price per share down to USD$5.26 at the end of the trading day. Subsequent premarket fluctuations saw the stock plummet by 19.20%, bringing it down to USD$4.25.

    Expanding Consumer Base

    MEDS stock continued to allocate resources toward the expansion of its drug procurement marketplace over the course of Q2 2021. The quarter reported having added roughly 195 new registered members, bumping the total number of registered members up to more than 12,700. The company also signed various enterprise retail partnerships to onboard new customers to its telehealth platform, partnering up with the likes of Brookshire Grocery, Winn-Dixie, and Big Y. MEDS stock’s Bonum Health product is now offered in 500 stores across all 50 states, increasing accessibility to its thousands of customers.

    MEDS Stock’s Partnerships

    MEDS stock also secured a group purchasing agreement with QualityCare Pharmacies, an independent pharmacy prescription drug buying group. QualityCare is the newest part of the company’s rapidly expanding GPO offering, aimed to drive substantial gains in wallet share amongst independent pharmacies on the TRxADE platform. MEDS stock also launched a government-oriented health passport solution with an accompanying mobile app, facilitating the expedition of post-Covid-19 reopening.

    MEDS Stock Revenue Reports

    Revenues for Q2 2021 were up to USD$1.9 million, down from the USD$6.6 million in the same quarter of the prior year. This year-over-year decrease was largely driven by non-recurring sales of personal protective equipment (PPE) in the 2020 quarter, in relation to global efforts to manage the outbreak of the Covid-19 pandemic.

    Additional Financials

    The second quarter of 2021 saw MEDS stock report gross profits in the amount of USD$0.8 million, representing 44.3% of the quarter’s revenues. This is comparable to the USD$2 million reported for the prior-year quarter, representing 30.4% of revenues. The substantial year-over-year increase in gross profit margin was largely driven by fewer lower margin PPE sales in the 2021 quarter. Operating expenses for the second quarter of 2021 came in at USD$3.4 million, up from the USD$2.5 million reported in the prior-year quarter. This increase was largely driven by an inventory investment loss of USD$1.2 million.

    Future Outlook for MEDS

    Armed with its expanding network of strategic collaborations and the success of its most recent financial reports, MEDS stock is poised to continue its trajectory of success. The company is keen to allocate resources so as to usher in further growth, with investors hoping for long-term increases in shareholder value.

  • Agile Therapeutics Inc. (AGRX) Stock Exhibits Minor Volatility Following Promising Q2 2021 Financial Reports

    Agile Therapeutics Inc. (AGRX) stock prices were down 3.45% as of market closing on July 26th, 2021, bringing the price per share down to USD$1.12 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 4.46%, bringing it up to USD$1.17.

    AGRX Stock Prescriptions Improved

    The second quarter of 2021 saw AGRX stock report total prescriptions coming in at 5,027, up a massive 171% from the numbers reported for the prior quarter. New prescriptions were up 103% over the quarter, reported at 2,857. These increases were driven by increases in the number of prescribers and growing refill rates. As of June 30th, 2021, the company reported more than 2,087 healthcare providers, while 2,033 prescriptions were dispensed as refills. Up 355% from the prior quarter. AGRX also reported an increase in the total number of prescriptions per prescriber.

    AGRX Stock’s Market Reach

    AGRX stock has continued expanding the market footprint of Twirla, with it being available to Medicaid patients across roughly 75%, either through traditional and/or managed Medicaid. This development sees Twirla cover roughly half of the total Medicaid transdermal TRx market with no restrictions. Based on claims, Twirla reports having access to roughly 55% of the commercial and government CHC market.

    Cost of Product Revenue

    Cost of product revenues for the quarter ended June 30th, 2021 was reported at USD$1.1 million and included direct and indirect expenses. These costs supported AGRX stock’s manufacturing and distribution efforts, including, but not limited to, personnel costs and roughly USD$500,000 of non-cash depreciation expense. These relatively fixed costs are expected to stay roughly the same as sales increase with expected volume increases.

    Additional Financials

    AGRX stock was selling units from validation batches until May 2021, with no associated product cost on account of the cost having been previously expensed already. Roughly 76% of the units sold over the second quarter of 2021 had an associated product cost, as will all future sales of the product. As of June 30th, 2021, the company reported USD$31.1 million in cash, cash equivalents, and marketable securities. This is compared to the USD$54.5 million reported as of December 31st, 2020.

    Future Outlook for AGRX

    With the company’s flagship Twirla gaining traction and snowballing in sales, AGRX stock is poised to capitalize on the increasing momentum. The company is keen to continue its trajectory of success as it effectively allocated its resources to stay lean. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.